Photo de stock - plitidepsin, has a much more potent antiviral efficacy against SARS-CoV-2 than the only antiviral approved to date, conceptual image.

Photo de stock: plitidepsin, has a much more potent antiviral efficacy against SARS-CoV-2 than the only antiviral approved to date, conceptual image.

Mots-clés utilisés

Choisir des mots clés multiples